These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

918 related items for PubMed ID: 19573471

  • 1. The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis.
    Rogowski W, Burch J, Palmer S, Craigs C, Golder S, Woolacott N.
    Health Technol Assess; 2009 Jun; 13(31):iii-iv, ix-xi, 1-77. PubMed ID: 19573471
    [Abstract] [Full Text] [Related]

  • 2. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation.
    Main C, Palmer S, Griffin S, Jones L, Orton V, Sculpher M, Henderson R, Sudlow C, Hawkins N, Riemsma R.
    Health Technol Assess; 2004 Oct; 8(40):iii-iv, xv-xvi, 1-141. PubMed ID: 15461878
    [Abstract] [Full Text] [Related]

  • 3. Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis.
    Greenhalgh J, Bagust A, Boland A, Dwan K, Beale S, Fleeman N, McEntee J, Dundar Y, Richardson M, Fisher M.
    Health Technol Assess; 2015 Apr; 19(29):1-130. PubMed ID: 25896573
    [Abstract] [Full Text] [Related]

  • 4. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C, Burch J, Suekarran S, Walker S, Bakhai A, Witte K, Harden M, Wright K, Woolacott N, Lorgelly P, Fenwick L, Palmer S.
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [Abstract] [Full Text] [Related]

  • 5. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.
    Greenhalgh J, Bagust A, Boland A, Martin Saborido C, Oyee J, Blundell M, Dundar Y, Dickson R, Proudlove C, Fisher M.
    Health Technol Assess; 2011 Sep; 15(31):1-178. PubMed ID: 21888837
    [Abstract] [Full Text] [Related]

  • 6. Clopidogrel: a pharmacoeconomic review of its use in patients with non-ST elevation acute coronary syndromes.
    Lyseng-Williamson KA, Plosker GL.
    Pharmacoeconomics; 2006 Sep; 24(7):709-26. PubMed ID: 16802846
    [Abstract] [Full Text] [Related]

  • 7. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
    Jones L, Griffin S, Palmer S, Main C, Orton V, Sculpher M, Sudlow C, Henderson R, Hawkins N, Riemsma R.
    Health Technol Assess; 2004 Oct; 8(38):iii-iv, 1-196. PubMed ID: 15461876
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical modelling.
    Robinson M, Palmer S, Sculpher M, Philips Z, Ginnelly L, Bowens A, Golder S, Alfakih K, Bakhai A, Packham C, Cooper N, Abrams K, Eastwood A, Pearman A, Flather M, Gray D, Hall A.
    Health Technol Assess; 2005 Jul; 9(27):iii-iv, ix-xi, 1-158. PubMed ID: 16022802
    [Abstract] [Full Text] [Related]

  • 9. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
    Kourlaba G, Fragoulakis V, Maniadakis N.
    Appl Health Econ Health Policy; 2012 Jul 01; 10(4):261-71. PubMed ID: 22667992
    [Abstract] [Full Text] [Related]

  • 10. Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention.
    Greenhalgh J, Bagust A, Boland A, Saborido CM, Fleeman N, McLeod C, Dundar Y, Dickson R, Proudlove C, Kolamunnage-Dona R, Fisher M.
    Health Technol Assess; 2010 May 01; 14 Suppl 1():31-8. PubMed ID: 20507801
    [Abstract] [Full Text] [Related]

  • 11. A cost-utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK.
    Karnon J, Bakhai A, Brennan A, Pandor A, Flather M, Warren E, Gray D, Akehurst R.
    Int J Cardiol; 2006 May 24; 109(3):307-16. PubMed ID: 16026869
    [Abstract] [Full Text] [Related]

  • 12. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease.
    Keller TT, Squizzato A, Middeldorp S.
    Cochrane Database Syst Rev; 2007 Jul 18; (3):CD005158. PubMed ID: 17636787
    [Abstract] [Full Text] [Related]

  • 13. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
    Kohli P, Udell JA, Murphy SA, Cannon CP, Antman EM, Braunwald E, Wiviott SD.
    J Am Coll Cardiol; 2014 Jan 28; 63(3):225-32. PubMed ID: 24140678
    [Abstract] [Full Text] [Related]

  • 14. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial.
    Chin CT, Roe MT, Fox KA, Prabhakaran D, Marshall DA, Petitjean H, Lokhnygina Y, Brown E, Armstrong PW, White HD, Ohman EM, TRILOGY ACS Steering Committee.
    Am Heart J; 2010 Jul 28; 160(1):16-22.e1. PubMed ID: 20598967
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of optimized antithrombotic therapy with aspirin, clopidogrel and enoxaparin in patients with non-ST segment elevation acute coronary syndromes in clinical practice.
    Heer T, Juenger C, Gitt AK, Bauer T, Towae F, Zahn R, Senges J, Zeymer U, Acute Coronary Syndromes (ACOS) Registry Investigators.
    J Thromb Thrombolysis; 2009 Oct 28; 28(3):325-32. PubMed ID: 19101783
    [Abstract] [Full Text] [Related]

  • 16. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation.
    Weintraub WS, Mahoney EM, Lamy A, Culler S, Yuan Y, Caro J, Gabriel S, Yusuf S, CURE Study Investigators.
    J Am Coll Cardiol; 2005 Mar 15; 45(6):838-45. PubMed ID: 15766816
    [Abstract] [Full Text] [Related]

  • 17. A cost-utility analysis of clopidogrel in patients with ST elevation acute coronary syndromes in the UK.
    Karnon J, Holmes MW, Williams R, Bakhai A, Brennan A.
    Int J Cardiol; 2010 Apr 30; 140(3):315-22. PubMed ID: 19106007
    [Abstract] [Full Text] [Related]

  • 18. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden.
    Lindgren P, Stenestrand U, Malmberg K, Jönsson B.
    Clin Ther; 2005 Jan 30; 27(1):100-10. PubMed ID: 15763611
    [Abstract] [Full Text] [Related]

  • 19. Rivaroxaban for Preventing Atherothrombotic Events in People with Acute Coronary Syndrome and Elevated Cardiac Biomarkers: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Pandor A, Pollard D, Chico T, Henderson R, Stevenson M.
    Pharmacoeconomics; 2016 May 30; 34(5):463-77. PubMed ID: 26689783
    [Abstract] [Full Text] [Related]

  • 20. The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation.
    Panattoni L, Brown PM, Te Ao B, Webster M, Gladding P.
    Pharmacoeconomics; 2012 Nov 01; 30(11):1067-84. PubMed ID: 22974536
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.